

The degradation pathways of glucagon in acidic solutions

Anjali B. Joshi^a, Elena Rus^b, Lee E. Kirsch^{a,*}

^a Division of Pharmaceutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA

^b Molecular Analysis Facility, The University of Iowa, Iowa City, IA 52242, USA

Received 2 March 2000; received in revised form 28 April 2000; accepted 1 May 2000

Abstract

Objective: Glucagon is a 29 amino acid peptide hormone that exhibits degradation via both chemical and physical pathways. The objective of the studies reported herein was to identify the degradation products and scheme for glucagon hydrolysis in acidic solutions. **Methods:** Solutions of glucagon in 0.01 N HCl (pH 2.5) were degraded at 60°C for 70 h. One isocratic and two gradient RP-HPLC methods were developed to separate the degradation products. Structure elucidation of the separated peaks was achieved using amino acid sequencing, amino acid analysis, and mass spectrometry. Degradation was carried out in the pH range 1.5–5 to check for changes in degradation scheme with pH. Authentic samples of degradation products were degraded under similar acidic conditions to confirm precursor successor relationships in the degradation scheme. **Results:** Sixteen major degradation products were isolated and identified. The major pathways of degradation were found to be aspartic acid cleavage at positions 9, 15, and 21 and glutaminyl deamidation at positions 3, 20, and 24. Cleavage occurred on both sides of Asp-15 but only on the C-terminal side of Asp-9 and Asp-21. Deamidation of the Asn residue at position 28 was not detected. © 2000 Elsevier Science B.V. All rights reserved.

Keywords: Degradation pathways; Deamidation; Glucagon; Glutaminyl; Hydrolysis; Peptide cleavage

1. Introduction

Glucagon is a polypeptide hormone that is used for the emergency treatment of insulin induced, sulphonylurea induced, and spontaneous hypoglycemia. It has the ability to raise blood glucose concentrations by increasing hepatic glycogenolysis through activation of liver phosphorylase and to stimulate insulin secretion by direct action on pancreatic β -cells. Recovery of consciousness is

usually achieved within 15–30 min of the injection whereupon oral glucose may be used to continue treatment (Marks, 1983). Glucagon also has the ability to reduce smooth muscle tone and motility. It is used as a diagnostic aid in radiologic procedures of the gastrointestinal tract that require a diminished tone and motility of the organ under study (Diamant and Picazo, 1983).


Glucagon for injection is a mixture of glucagon hydrochloride with one or more suitable, dry diluents supplied in single-dose or multiple-dose containers. The pH of the reconstituted solution is between 2.5 and 3.0 (US Pharmacopeia 24, 1999).

* Corresponding author. Fax: +1-319-3359349.

E-mail address: lee-kirsch@uiowa.edu (L.E. Kirsch).

Thus the stability of glucagon in acidic aqueous solutions is relevant to drug product quality.

Structurally, glucagon contains 29 amino acids (Fig. 1). In the crystalline state, a completely helical conformation was proposed for glucagon (Sasaki et al., 1975). However, optical rotatory dispersion (Gratzer et al., 1968) and circular dichroism studies (Sreere and Brooks, 1969) of glucagon in dilute aqueous solutions revealed a predominantly random coil conformation with at most 15% α -helix at the C-terminal end. The molecule has an isoelectric point of ~ 7 and exhibits very low solubility (< 0.1 mg/ml) in the approximate pH range of 4–8. It is readily soluble (> 10 mg/ml) at pH values less than 3 or greater than 9 (Bromer, 1983). It is known to self-associate at high concentrations and forms aggregates and gels at mild temperatures in acidic and basic



Separation method (see text)	Arbitrary Peak #	Fragment sequence
A	I	FVQWLMNT 22-29
	II	FVEWLMNT (22-29) _{d₂₄}
	III	SRRAQDFVQWLMNT 16-29
	IV	SRRAQDFVQWLMNT (16-29) _{d₂₄}
	V	YSKYL 10-14
	VI	TSKYLSRRAQDFVQWLMNT 10-29
	VII	TSKYLSRRAQDFVQWLMNT (10-29) _{d₂₄}
B	VIII	HSQGTFTSD 1-9
	IX	HSEGTFTSD (1-9) _{d₃}
	X	YSKYLSRRAQD 10-21
	XI	YSKYLSRRAED (10-21) _{d₂₀}
	XII	YSKYLD 10-15
C	XIII	HSQGTFTSDYSKYLSRRAQD 1-21
	XIV	HSQGTFTSDYSKYLD 1-15
	XV	HSQGTFTSDYSKYL 1-14

Fig. 1. Sequences of glucagon and its major degradation products in acidic aqueous solutions. The sequence of each degradation fragment is denoted using the one-letter abbreviations for the amino acids and by the numbers of the first and last amino acid residues. Deamidated fragments are denoted by parentheses followed by ' d_n ' where ' n ' is the number of the glutamine residue which deamidates.

solutions. The aggregation is promoted by salt, increased pH (within the acid range of solubility), agitation, and increased temperature up to 30°C (Beaven et al., 1969). Aggregation is accompanied by an increase in secondary structure in the form of anti-parallel β -sheets (Gratzer et al., 1968).

The degradation pathways of glucagon have not been reported. In one study, glucagon degradation in 0.03 N HCl at 105°C was found to release three aspartic acid residues in 13 h (Schultz, 1967). The possibility of iso-aspartyl formation at the position of Asp-9 at neutral pH has also been suggested (Ota et al., 1987). The objective of the studies presented herein was to identify the degradation products and scheme for glucagon hydrolysis in acidic solutions.

2. Materials and methods

2.1. Materials

Purified porcine glucagon was obtained from Lilly Research Laboratories (Indianapolis, IN). Sodium dihydrogen phosphate, *o*-phosphoric acid, acetic acid, formic acid, hydrochloric acid, trifluoroacetic acid, potassium chloride, sodium formate, and sodium acetate were from Fisher (Springfield, NJ). All chemicals were of reagent grade and used as received. Solvents used for chromatography were HPLC grade. Cellulose ester dialysis membranes were from Spectrum (Houston, TX). Degradation product fragments were synthesized manually by SynPep Corporation (Dublin, CA).

2.2. Degradation of glucagon and glucagon fragments in acidic pH range

Aqueous glucagon solutions (0.1–1 mg/ml) were degraded at 60°C in the pH range 1.5–5 using dilute HCl, phosphate, formate, or acetate buffers. Degradation was allowed to proceed to two to three half-lives. Aliquots were removed from reaction mixtures at various time intervals and stored at 4°C until analyzed. Authentic degradation products were subject to hydrolysis at pH 1.5 and 2.5 under conditions identical to those used for glucagon.

2.3. Separation of degradation products

High performance liquid chromatography (HPLC) analyses were performed using a Shimadzu RP-HPLC system consisting of an SCL-10AVP system controller, LC-10ATVP pumps, SIL-10ADVP auto-injector, SPD-10AVP UV-VIS detector, and a CTO-10ASVP column oven. Chromatograms were integrated and data stored using Class VP Chromatography Data System software (Version 4.2).

Separation of degradation products was achieved on a Lichrospher RP-18, 4.6×250 mm, 5μ -column using isocratic elution (Method A). The mobile phase contained 29:71 acetonitrile:buffer (buffer = 0.1 M sodium phosphate monobasic and 0.002 M cysteine free base, adjusted to pH 2.6 with 85% phosphoric acid). Flow rate was 1.0 ml/min, detection was at 214 nm, and column temperature was 35°C. Degradation products that were unresolved with the isocratic method were separated by gradient elution using a Zorbax 300SB C8, 4.6×250 mm, 5μ column. The mobile phase contained methanol and a 0.024% solution of trifluoroacetic acid in water. The gradient used was 5–35% methanol in 30 min (Method B). Flow rate was 1.0 ml/min, detection was at 214 nm, and column temperature was 25°C. Another gradient method (Method C) was developed in an attempt to separate additional degradation peaks using the same column and mobile phase as the previous gradient method. The gradient was 5–50% methanol in 90 min. Flow rate was 1.0 ml/min, detection was at 214 nm, and column temperature was 25°C.

Degradation product peaks were collected from repeated 200 μ l reaction mixture samples using a FRC 10A fraction collector (Shimadzu). Seven peaks were collected with the isocratic method (Method A), five more peaks with the first gradient method (Method B), and an additional three peaks with the second gradient method (Method C). The collection procedure was validated by re-injecting peak fractions back on the column to check peak integrity. Individual peaks were collected in flat top 1.5 ml polypropylene microcentrifuge tubes (Fisher Scientific) and stored in the refrigerator at 4°C until analysis. Since analysis of

the fractions was typically done 4–7 days after fraction collection, the stability of the fractions at 4°C was evaluated. No significant degradation of peptide fractions was observed up to 18 days at 4°C.

2.4. Degradation product identification

Structure elucidation of degradation products was done using either amino acid sequencing, amino acid analysis, or mass spectrometry. Most of the fractions were identified using more than one method.

Amino acid analysis was performed by hydrolyzing an aliquot of each fraction using 100 μ l of 6 N HCl at 110°C for 24 h. When hydrolysis was completed, the vials were placed in a SpeedVac® (Model SC210A) where all the residual liquid was removed by evaporation. Sample hydrolysates were then re-dissolved in sodium citrate buffer diluent. A Beckman 6300 high-performance ion-exchange analyzer was used to analyze each sample. Separation was done using a 12 cm hydrolysate column and a three-step temperature program in combination with three sodium citrate buffers to separate amino acids in various charged states. Standards consisting of a mixture of all amino acids plus an internal standard were also hydrolyzed. The system used ninhydrin to react with the amino acid giving a color reaction. The intensity of the color was proportional to the concentration of amino acid.

For sequencing, fraction aliquots were concentrated in a SpeedVac® and passed through a Prosorb sample preparation cartridge (Perkin Elmer). The adsorbent filter in these cartridges draws sample solution through a membrane by capillary action. The membrane immobilizes proteins and peptides while buffer components that could potentially interfere with sequencing pass through. The process not only desalts but also concentrates the sample. The membrane holding the peptide was directly loaded on the sequencer. Sequencing was done using an Applied Biosystems 492 automatic sequencer with an on-line PTH analyzer. A standard consisting of a mixture of all amino acids was first injected to obtain reference retention times for each amino

acid. One fraction was assigned more than one sequence (one major and one minor) due to the presence of a mixture of peptides.

Degradation product identity was also verified using Fast Atom Bombardment Mass Spectrometry (FABMS). The instrument used was a Hewlett Packard 1100 LCMSD. Organic solvents present in peak fractions collected with the isocratic method (Method A) were removed by evaporation under nitrogen. Sample peak fractions were then desalted using cellulose ester dialysis membranes (MWCO = 500). De-ionized water was used as the dialysis medium and was changed twice daily. The extent of dialysis was monitored by measuring the conductivity of the dialysate on an Orion Model 160 conductivity meter. Dialysis was stopped when the conductivity measurement was close to that of pure de-ionized water. The dialyzed fractions were then freeze dried (Virtis Advantage lyophilizer) and analyzed by FABMS. Peak fractions collected using the gradient methods (Methods B and C) were simply concentrated in a SpeedVac[®] before FABMS analysis since these fractions contained only water and volatile solvents.

To verify the sequencing results, two peaks obtained by isocratic elution (Method A) were analyzed by FABMS. The molecular ion masses obtained corresponded to the fragments obtained by sequencing. Hence, additional FABMS analyses were not performed on fractions that were sequenced. However, FABMS was used to confirm every sequence obtained with amino acid analysis alone.

3. Results

3.1. Chromatographic separation of degradation products

Chromatographic separation of degraded glucagon using isocratic elution (Method A) gave seven major degradation peaks (Peaks I–VII, Fig. 2). Sequencing of these products revealed that they were peptide fragments containing the C-terminus of glucagon. A gradient elution method (Method B) was developed to separate the corre-

sponding fragments containing the more polar amino acids of the N-terminus end. An additional five peaks were obtained (Peaks VIII–XII, Fig. 3). A second gradient method (Method C) was developed to check for additional degradation products. This method involved a slow gradient (90 min) from 5 to 50% methanol and yielded several peaks. The peak at retention time of 5.5 min was found to be the same as peak XII obtained with Method B (Fig. 3). The peaks eluting at 35.3, 59.3 min, and 69.3 min were found to be the same as peak I, peak III, and peak V respectively, obtained by Method A (Fig. 2). These peak assignments were made by co-injecting peak fractions or authentic samples of peaks XII, I, III, and V and comparing retention times. The peak eluting at 72.1 min was glucagon. Thus, three new peaks, at 15.3, 20.2, and 26.6 min were obtained by Method C (peaks XIII, XIV, and XV in Fig. 4).

An overlay of sample chromatograms obtained from degradation reactions conducted over the pH range 2.5–5 (Fig. 5) demonstrated that the retention times of the major degradation product peaks were similar at pH 2.5 and 3.5. At higher pH values (4.5 and 5), the chromatograms were somewhat similar but separation quality was compromised by glucagon aggregation.

3.2. Degradation product identities

Of the seven peaks obtained by Method A (Fig. 2), peaks I, III, and V were composed of peptide fragments 22–29, 16–29, and 10–29 respectively, indicating that peptide cleavage had occurred on the C-terminal side of Asp-21, Asp-15, and Asp-9. Peaks II, IV, and VI eluted immediately after peaks I, III, and V (Fig. 2) and were found to be the deamidated forms of fragments 22–29 (peak I), 16–29 (peak III), and 10–29 (peak V) wherein Gln-24 converted to Glu-24. Peak VII was the deamidated form of glucagon with Glu at position 24. A small peptide fragment starting at Tyr-10 co-eluted with deamidated 16–29 in peak IV. Both these peptides could be detected through separate PTH-AA signals. However, both fragments have Asp as their sixth residue, hence the chromatogram for the sixth cycle of sequencing




Fig. 2. Separation of degradation products of glucagon by isocratic elution using RP-HPLC Method A (column was a Lichrospher RP-18, mobile phase was 29:71 acetonitrile:buffer, buffer = 0.1 sodium phosphate monobasic and 0.002 M cysteine free base, adjusted to the pH 2.6 with 85% phosphoric acid).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.